PEG化タンパク質の世界市場レポート 2025年

PEG化タンパク質市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR13.7％で28億米ドルに成長します。予測期間の成長は、希少疾患への投資の増加、バイオ医薬品産業の急成長、精密医療の調整、生物学的製剤のバイオシミラー版との競合激化、革新的な市場参入戦略の採用などに起因すると考えられます。予測期間における主な動向としては、デジタルヘルス技術の統合、次世代ペジル化技術、精密医療のためのオーダーメイド製剤、併用療法への注力、患者中心のヘルスケアモデルへの移行などが挙げられます。

生活習慣病の有病率の増加は、今後数年間のPEG化タンパク質市場の成長を牽引すると予想されます。生活習慣病とは、主に不健康な食事、運動不足、喫煙などの生活習慣やライフスタイルの選択ミスによって引き起こされる健康状態のことです。これらの病気は、身体活動の減少、加工食品の多い食事、ストレスレベルの上昇などの要因により、より一般的になってきています。PEG化タンパク質は、心血管疾患、糖尿病、一部のがんなどの症状に対する治療薬の有効性、持続時間、標的送達を改善することにより、生活習慣病の治療に使用されます。例えば、2024年5月、英国の政府機関であるOffice for Health Improvement and Disparitiesは、2022-2023年にイングランドの18歳以上の成人の約64.0％が過体重または肥満と分類され、2021-2022年の63.8％からわずかに増加したと報告しました。その結果、生活習慣病の有病率の上昇がPEG化タンパク質市場の成長に寄与しています。

PEG化タンパク質市場の主なプレーヤーは、競争力を維持するためにPEG化試薬などの革新的な製品の開発に注力しています。PEG化試薬は、生体分子にポリエチレングリコール（PEG）鎖を結合させ、様々な生物医学的応用のためにその特性を変更する化学化合物です。例えば、米国を拠点とする食品添加物と酵素のサプライヤーであるCreative Enzymes社は、2023年5月に標的ドラッグデリバリー用のDSPE-PEG-Maleimideを発表しました。DSPE-PEG-マレイミドは、DSPEリン脂質とマレイミドを含む直鎖状のヘテロ二官能性PEG化試薬で、PEG化リポソームやミセルを調製するための貴重な自己組織化試薬として機能し、標的ドラッグデリバリーで一般的に使用されるチオールまたはシステイン反応性マレイミド基を提供します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界PEG化タンパク質PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のPEG化タンパク質市場：成長率分析
• 世界のPEG化タンパク質市場の実績：規模と成長, 2019-2024
• 世界のPEG化タンパク質市場の予測：規模と成長, 2024-2029, 2034F
• 世界PEG化タンパク質総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のPEG化タンパク質市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 消耗品とサービス
• PEG化キットおよび試薬
• 単官能性直鎖PEG
• 二官能性PEG
• その他の製品
• 世界のPEG化タンパク質市場タンパク質の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• コロニー刺激因子
• インターフェロン
• エリスロポエチン
• 組換え因子VII
• その他のタンパク質の種類
• 世界のPEG化タンパク質市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• がん治療
• 肝炎
• 慢性腎臓病
• 血友病
• 多発性硬化症
• 胃腸障害
• その他の用途
• 世界のPEG化タンパク質市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 医薬品
• バイオテクノロジー企業
• 契約調査機関
• 学術調査機関
• 世界のPEG化タンパク質市場消耗品とサービスの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 消耗品
• サービス（契約サービス、PEG化サービス）
• 世界のPEG化タンパク質市場PEG化キットおよび試薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• PEG化キット
• 試薬
• 世界のPEG化タンパク質市場、単官能直鎖PEGのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• タンパク質修飾のための単官能性PEG
• 世界のPEG化タンパク質市場二官能性PEGのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• タンパク質修飾のための二官能性PEG
• 世界のPEG化タンパク質市場、その他の製品のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 共役
• PEG化医薬品および治療薬

第7章 地域別・国別分析

• 世界のPEG化タンパク質市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のPEG化タンパク質市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• PEG化タンパク質市場：競合情勢
• PEG化タンパク質市場：企業プロファイル
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Gilead Sciences Inc.
• Novo Nordisk A/S
• Evonik Industries AG
• Viatris Inc.
• Regeneron Pharmaceuticals Inc.
• Biogen Inc.
• Vertex Pharmaceuticals Incorporated
• Lonza Group Ltd.
• Jazz Pharmaceuticals plc
• Ipsen Pharma
• Kyowa Kirin Co. Ltd.
• WuXi Biologics
• BioMarin Pharmaceutical Inc.
• Ligand Pharmaceuticals Incorporated
• Zydus Cadila

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• PEG化タンパク質市場2029：新たな機会を提供する国
• PEG化タンパク質市場2029：新たな機会を提供するセグメント
• PEG化タンパク質市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

PEGylated proteins are therapeutic proteins covalently bonded to polyethylene glycol (PEG), a process aimed at enhancing their pharmacokinetic properties and reducing immunogenicity, thus improving their therapeutic efficacy. These modified proteins find application in various medical fields, including drug delivery, diagnostics, and targeted therapy, offering prolonged action and potentially improving patient outcomes.

The primary products within the PEGylated proteins market include consumables and services, pegylation kits and reagents, monofunctional linear PEGs, bifunctional PEGs, and others. Consumables and services constitute a broad category encompassing products and services vital for PEGylated protein research and development, including kits, reagents, and various support services. The proteins themselves cover a range of types such as colony-stimulating factors, interferons, erythropoietin, recombinant factor VII, and others, serving diverse applications including cancer treatment, hepatitis, chronic kidney diseases, hemophilia, multiple sclerosis, gastrointestinal disorders, and more. End users of these products and services include pharmaceutical companies, biotechnology firms, contract research organizations, and academic research institutes.

The PEGylated proteins market research report is one of a series of new reports from The Business Research Company that provides PEGylated proteins market statistics, including the PEGylated proteins industry global market size, regional shares, competitors with the PEGylated proteins market share, detailed PEGylated proteins market segments, market trends, and opportunities, and any further data you may need to thrive in the PEGylated proteins industry. These PEGylated proteins market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pegylated proteins market size has grown rapidly in recent years. It will grow from $1.47 billion in 2024 to $1.68 billion in 2025 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to improved therapeutic efficacy, a growing aging population, demand for long-acting formulations, enhanced drug safety profiles, and expanding applications including targeted drug delivery systems.

The pegylated proteins market size is expected to see rapid growth in the next few years. It will grow to $2.8 billion in 2029 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to increasing investment in rare diseases, rapid growth of the biopharmaceutical industry, precision medicine tailoring, increasing competition from biosimilar versions of biologic drugs, and adoption of innovative market access strategies. Major trends in the forecast period include the integration of digital health technologies, next-generation pegylation technologies, customized formulations for precision medicine, a focus on combination therapies, and a shift towards patient-centric healthcare models.

The growing prevalence of lifestyle diseases is expected to drive the growth of the PEGylated proteins market in the coming years. Lifestyle diseases are health conditions primarily caused by poor habits and lifestyle choices, such as an unhealthy diet, lack of physical activity, and smoking. These diseases are becoming more common due to factors like reduced physical activity, diets rich in processed foods, and heightened stress levels. PEGylated proteins are used in the treatment of lifestyle diseases by improving the effectiveness, duration, and targeted delivery of therapeutic agents for conditions like cardiovascular diseases, diabetes, and some cancers. For example, in May 2024, the Office for Health Improvement and Disparities, a UK-based government agency, reported that in 2022-2023, approximately 64.0% of adults aged 18 and over in England were classified as overweight or obese, a slight increase from 63.8% in 2021-2022. As a result, the rising prevalence of lifestyle diseases is contributing to the growth of the PEGylated proteins market.

Key players in the PEGylated proteins market are focusing on the development of innovative products such as PEGylation reagents to maintain a competitive edge. PEGylation reagents are chemical compounds that attach polyethylene glycol (PEG) chains to biomolecules, modifying their properties for various biomedical applications. For instance, Creative Enzymes, a US-based supplier of food additives and enzymes, introduced DSPE-PEG-Maleimide in May 2023 for targeted drug delivery. DSPE-PEG-Maleimide is a linear heterobifunctional PEGylation reagent containing DSPE phospholipids and maleimide, serving as a valuable self-assembly reagent for preparing PEGylated liposomes or micelles and providing thiol or cysteine reactive maleimide groups, commonly used in targeted drug delivery.

In February 2022, Merck KGaA, a pharmaceutical company based in Germany, acquired Exelead Inc. for $793 million to bolster its presence in the growing market for mRNA therapeutics. Exelead Inc., a US-based biopharmaceutical company specializing in GMP-certified PEGylation services for use in manufacturing process development, is expected to enhance Merck KGaA's capabilities in this sector.

Major companies operating in the PEGylated proteins market are Merck & Co. Inc., Bayer AG, Bristol Myers Squibb Company, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc., Novo Nordisk A/S, Evonik Industries AG, Viatris Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Lonza Group Ltd., Jazz Pharmaceuticals plc, Ipsen Pharma, Kyowa Kirin Co. Ltd., WuXi Biologics, BioMarin Pharmaceutical Inc., Ligand Pharmaceuticals Incorporated, Zydus Cadila, Enzon Pharmaceuticals Inc.

North America was the largest region in the PEGylated Proteins market in 2024. The regions covered in the PEGylated proteins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the PEGylated proteins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The PEGylated proteins market consists of revenues earned by entities by providing services such as analytical services and contract manufacturing services for PEGylated protein. The market value includes the value of related goods sold by the service provider or included within the service offering. The PEGylated proteins market also includes sales of PEGylated enzymes, PEGylated antibodies, and PEGylated hormones. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

PEGylated Proteins Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pegylated proteins market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pegylated proteins ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pegylated proteins market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Consumable And Services; PEGylation Kits And Reagents; Monofunctional Linear PEGs; Bifunctional PEGs; Services; Other Products
• 2) By Protein Type: Colony Stimulating Factors; Interferons; Erythropoietin; Recombinant Factor VII; Other Protein Types
• 3) By Application: Cancer Treatment; Hepatitis; Chronic Kidney Diseases; Hemophilia; Multiple Sclerosis; Gastrointestinal Disorders; Other Applications
• 4) By End User: Pharmaceuticals; Biotechnology Companies; Contract Research Organizations; Academic Research Institutes
• Subsegments:
• 1) By Consumable And Services: Consumables; Services (Contract Services, PEGylation Services)
• 2) By PEGylation Kits And Reagents: PEGylation Kits; Reagents
• 3) By Monofunctional Linear PEGs: Monofunctional PEGs For Protein Modification
• 4) By Bifunctional PEGs: Bifunctional PEGs For Protein Modification
• 5) By Other Products: Conjugates; PEGylated Drugs And Therapeutics
• Companies Mentioned: Merck & Co. Inc.; Bayer AG; Bristol Myers Squibb Company; AstraZeneca PLC; Roche Holding AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. PEGylated Proteins Market Characteristics

3. PEGylated Proteins Market Trends And Strategies

4. PEGylated Proteins Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global PEGylated Proteins Growth Analysis And Strategic Analysis Framework

• 5.1. Global PEGylated Proteins PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global PEGylated Proteins Market Growth Rate Analysis
• 5.4. Global PEGylated Proteins Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global PEGylated Proteins Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global PEGylated Proteins Total Addressable Market (TAM)

6. PEGylated Proteins Market Segmentation

• 6.1. Global PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Consumable And Services
• PEGylation Kits And Reagents
• Monofunctional Linear PEGs
• Bifunctional PEGs
• Other Products
• 6.2. Global PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Colony Stimulating Factors
• Interferons
• Erythropoietin
• Recombinant Factor VII
• Other Protein Types
• 6.3. Global PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cancer Treatment
• Hepatitis
• Chronic Kidney Diseases
• Hemophilia
• Multiple Sclerosis
• Gastrointestinal Disorders
• Other Applications
• 6.4. Global PEGylated Proteins Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pharmaceuticals
• Biotechnology Companies
• Contract Research Organizations
• Academic Research Institutes
• 6.5. Global PEGylated Proteins Market, Sub-Segmentation Of Consumable And Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Consumables
• Services (Contract Services, PEGylation Services)
• 6.6. Global PEGylated Proteins Market, Sub-Segmentation Of PEGylation Kits And Reagents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• PEGylation Kits
• Reagents
• 6.7. Global PEGylated Proteins Market, Sub-Segmentation Of Monofunctional Linear PEGs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monofunctional PEGs For Protein Modification
• 6.8. Global PEGylated Proteins Market, Sub-Segmentation Of Bifunctional PEGs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Bifunctional PEGs For Protein Modification
• 6.9. Global PEGylated Proteins Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Conjugates
• PEGylated Drugs And Therapeutics

7. PEGylated Proteins Market Regional And Country Analysis

• 7.1. Global PEGylated Proteins Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global PEGylated Proteins Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific PEGylated Proteins Market

• 8.1. Asia-Pacific PEGylated Proteins Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China PEGylated Proteins Market

• 9.1. China PEGylated Proteins Market Overview
• 9.2. China PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India PEGylated Proteins Market

• 10.1. India PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan PEGylated Proteins Market

• 11.1. Japan PEGylated Proteins Market Overview
• 11.2. Japan PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia PEGylated Proteins Market

• 12.1. Australia PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia PEGylated Proteins Market

• 13.1. Indonesia PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea PEGylated Proteins Market

• 14.1. South Korea PEGylated Proteins Market Overview
• 14.2. South Korea PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe PEGylated Proteins Market

• 15.1. Western Europe PEGylated Proteins Market Overview
• 15.2. Western Europe PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK PEGylated Proteins Market

• 16.1. UK PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany PEGylated Proteins Market

• 17.1. Germany PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France PEGylated Proteins Market

• 18.1. France PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy PEGylated Proteins Market

• 19.1. Italy PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain PEGylated Proteins Market

• 20.1. Spain PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe PEGylated Proteins Market

• 21.1. Eastern Europe PEGylated Proteins Market Overview
• 21.2. Eastern Europe PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia PEGylated Proteins Market

• 22.1. Russia PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America PEGylated Proteins Market

• 23.1. North America PEGylated Proteins Market Overview
• 23.2. North America PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA PEGylated Proteins Market

• 24.1. USA PEGylated Proteins Market Overview
• 24.2. USA PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada PEGylated Proteins Market

• 25.1. Canada PEGylated Proteins Market Overview
• 25.2. Canada PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America PEGylated Proteins Market

• 26.1. South America PEGylated Proteins Market Overview
• 26.2. South America PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil PEGylated Proteins Market

• 27.1. Brazil PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East PEGylated Proteins Market

• 28.1. Middle East PEGylated Proteins Market Overview
• 28.2. Middle East PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa PEGylated Proteins Market

• 29.1. Africa PEGylated Proteins Market Overview
• 29.2. Africa PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. PEGylated Proteins Market Competitive Landscape And Company Profiles

• 30.1. PEGylated Proteins Market Competitive Landscape
• 30.2. PEGylated Proteins Market Company Profiles
  • 30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis

31. PEGylated Proteins Market Other Major And Innovative Companies

• 31.1. Gilead Sciences Inc.
• 31.2. Novo Nordisk A/S
• 31.3. Evonik Industries AG
• 31.4. Viatris Inc.
• 31.5. Regeneron Pharmaceuticals Inc.
• 31.6. Biogen Inc.
• 31.7. Vertex Pharmaceuticals Incorporated
• 31.8. Lonza Group Ltd.
• 31.9. Jazz Pharmaceuticals plc
• 31.10. Ipsen Pharma
• 31.11. Kyowa Kirin Co. Ltd.
• 31.12. WuXi Biologics
• 31.13. BioMarin Pharmaceutical Inc.
• 31.14. Ligand Pharmaceuticals Incorporated
• 31.15. Zydus Cadila

32. Global PEGylated Proteins Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The PEGylated Proteins Market

34. Recent Developments In The PEGylated Proteins Market

35. PEGylated Proteins Market High Potential Countries, Segments and Strategies

• 35.1 PEGylated Proteins Market In 2029 - Countries Offering Most New Opportunities
• 35.2 PEGylated Proteins Market In 2029 - Segments Offering Most New Opportunities
• 35.3 PEGylated Proteins Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer